Figure 5
From: Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
The tumor masses in the different groups (n=9). BALB/c mice were subcutaneously inoculated with 4T1 cells. After 7 days, the mice in each group were subcutaneously injected with E5 every other day and intraperitoneally treated with paclitaxel (PTX) (a) or cyclophosphamide (CTX) (b) once a week. * represents P<0.05. ** represents P<0.01.
